oropharyngeal cancer – Page 3

Aspen Dental Practices Donate More Than $20,000 To The Oral Cancer Foundation For Oral Cancer Awareness Month

Source: www.pharmiweb.com.orgAuthor: Aspen Dental SYRACUSE, N.Y., May 31, 2016 /PRNewswire/ -- Aspen Dental–branded practices will donate $22,375 to The Oral Cancer Foundation (OCF) as part of a program that contributed $5 for each ViziLite® oral cancer screening conducted during April for Oral Cancer Awareness Month. In total, more than 4,000 patients were screened across more than 550 practices in 33 states. Since 2010, Aspen Dental-branded practices have donated more than $105,000 to OCF. "Approximately 48,250 people in the U.S. will be diagnosed with an oral or oropharyngeal cancer this year; and of those only about 57% will be alive in five years," said Natalie Riggs, Director of Special Projects for The Oral Cancer Foundation. In 2016 we estimate that 9500 individuals will lose their lives to oral cancers and we are grateful for the support from Aspen Dental practices in helping us raise awareness and aiding in our efforts to fight this disease." Oral cancer is frequently preceded by visible pre-malignant lesions and can be diagnosed at a much earlier stage (I or II) with ViziLite® Plus, a specially designed light technology. When caught early and treated, the survival rate is 80 to 90 percent. "We're working to educate our patients about the risk factors, warning signs and symptoms associated with oral cancer so that we can help them catch the disease before it progresses," said Dr. Murali Lakireddy, a general dentist who owns Aspen Dental offices in Ohio. "Many of our patients do not think about oral cancer when they go to [...]

Charlotte Parker2016-06-16T10:28:42-07:00June, 2016|OCF In The News, Oral Cancer News|

Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma

Source: www.aacr.orgAuthor: AACR Newsroom Staff NEW ORLEANS — Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with single-agent chemotherapy of the investigator’s choice, according to results from the CheckMate-141 phase III clinical trial presented here at the AACR Annual Meeting 2016, April 16-20. “Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly, and patients have a very poor prognosis,” said Maura L. Gillison, MD, PhD, a professor in the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. “Treatment usually involves single-agent chemotherapy. However, no therapy has been shown to improve survival for this patient population. New treatment options are desperately needed. “This study is the first randomized clinical trial to clearly demonstrate improved overall survival for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma,” continued Gillison. “We hope that the results will establish nivolumab as a new standard of care option for this patient population and thereby fulfill a huge unmet need.” CheckMate-141 was a randomized, phase III clinical trial designed to determine whether the PD-1 inhibitor nivolumab could extend overall survival for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma compared with treatment of the investigator’s choice, which was any of the commonly used therapeutics docetaxel, methotrexate, or [...]

Charlotte Parker2016-04-19T10:49:39-07:00April, 2016|OCF In The News, Oral Cancer News|

The Oral Cancer Foundation’s Founder, Brian R. Hill, honored by the Global Oral Cancer Forum – International oral cancer community honor his accomplishments in the field.

Source: www.prnewswire.comAuthor: The Oral Cancer Foundation NEWPORT BEACH, Calif., March 10, 2016 /PRNewswire-USNewswire/ -- At the recent Global Oral Cancer Forum (GOCF), Brian R. Hill, Executive Director and Founder of the Oral Cancer Foundation (OCF), was honored for his work as an advocate and innovative thinker in the oral cancer arena. The GOCF organizers and community awarded Hill the 2016 Global Oral Cancer Forum Commitment, Courage and Innovation Leadership Award for his dedication and contributions to the field of oral cancer over the last 18 years. Upon accepting the award, Hill received a standing ovation from those in attendance, which included global oral cancer thought leaders, researchers, treatment physicians, other non-profit organizations and representatives from various government agencies, including the National Institutes of Health / National Cancer Institute, and the World Health Organization (WHO). When asked about being honored Hill said, "In the beginning and for many years I was alone at OCF and it was just the seed of an idea. Those grassroots efforts matured into a robust network of important relationships with a common goal. Today OCF is so much more than just me and my singular efforts. Through the benevolence of the many OCF supporters, particularly in the RDH, dental/medical professional communities and survivor groups, OCF has grown into a powerful national force for proactive change of the late discovery paradigm, access to quality information, disease and patient advocacy, funding of research, and patient support." Hill acknowledges that he had the mentorship of some of the brightest minds [...]

Charlotte Parker2016-03-11T10:35:36-07:00March, 2016|OCF In The News, Oral Cancer News|

Immunotherapy Continues to Advance in Head and Neck Cancer

Source: www.onclive.comAuthor: Megan Garlapow, PhD Concomitant administration of motolimod with cetuximab (Erbitux) increases the innate and adaptive immune response in the blood and the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC), overcoming negative prognostic biomarkers of cetuximab therapy alone, according to the biomarker data from a recent phase Ib clinical trial that was presented at the 2016 Head and Neck Cancer Symposium. The trial was recently amended to add nivolumab to the combination of cetuximab and motolimod. Dr. Robert Ferris, MD PhD “We know that PD-1 and PD-L1 are overexpressed in head and neck cancer, and so it was somewhat irresistible to combine our baseline treatment of cetuximab and motolimod with the PD-L1 inhibition pathway. EGFR itself drives PD-L1, so combining cetuximab with anti-PD-1 inhibitor makes sense. So, we’ve amended this trial. We’re now accruing to treatment with cetuximab, motolimod, and the anti–PD-L1 nivolumab in this trial,” said lead author Robert Ferris, MD, PhD, professor, Departments of Otolaryngology, Radiation Oncology, and Immunology, Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. According to the authors of the phase Ib data presented at the symposium, the rationale for combining cetuximab with motolimod (VTX2337) as neoadjuvant therapy was that cetuximab induces cellular immunity that correlates with neoadjuvant clinical response. The phase I dose-escalation and safety of the combination had been established (NCT 01334177). This study of neoadjuvant cetuximab and motolimod had accrued 14 patients with HNSCC that was stage II-IV, resectable, and located in the oropharynx, [...]

Charlotte Parker2016-02-29T10:49:56-07:00February, 2016|Oral Cancer News|

NCCN Is ‘Vague,’ So Study Clarifies H&N Cancer Follow-up

Source: www.medscape.comAuthor: Nick Mulcahy Clinical guidelines can sometimes be slow to respond to epidemiology. Take the case of oropharyngeal cancers that are associated with human papillomavirus (HPV) infection. They are increasingly common in the United States and, as several studies have demonstrated, have better survival than cancers of this type that are not HPV-positive. Nonetheless, one of the beacons in oncology care, the National Comprehensive Cancer Network (NCCN), recommends the same follow-up care guidance for oropharynx squamous cell carcinoma whether it is associated with HPV or not, according to two experts. For post-treatment follow-up, including recurrence detection, "the NCCN guidelines are one-size-fits-all," said Jessica Frakes, MD, a radiation oncologist at the Moffitt Cancer Center and Research Institute in Tampa, Florida. She spoke during a press briefing at the Multidisciplinary Head and Neck Cancer Symposium 2016 in Scottsdale, Arizona. "You are exactly right: the NCCN is fairly vague about when to perform imaging," said Christine Gourin, MD, an otolaryngologist at Johns Hopkins University in Baltimore, who moderated the press briefing. Dr Frakes and her colleagues have stepped into this informational breach with a new study that might help clinicians gain clarity on the use of surveillance imaging in HPV-positive oropharyngeal cancer and reduce its frequency. "The purpose of our study is to determine when these patients fail and when they have side effects so we know how to guide optimal follow-up," Dr Frakes explained. The study authors examined 246 cases of nonmetastatic HPV-positive oropharynx squamous cell carcinoma treated with radiation therapy at [...]

Charlotte Parker2016-02-23T12:17:36-07:00February, 2016|Oral Cancer News|

Excitement at new cancer treatment

Source: www.news.doximity.comAuthor: James Gallagher A therapy that retrains the body's immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission. White blood cells were taken from patients with leukaemia, modified in the lab and then put back. But the data has not been published or reviewed and two patients are said to have died from an extreme immune response. Experts said the trial was exciting, but still only "a baby step." The news bubbled out of the American Association for the Advancement of Science's annual meeting in Washington DC. The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live. He told the conference that: "The early data is unprecedented." Re-training In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue. The researchers genetically modified the t-cells to engineer a new targeting mechanism - with the technical name of chimeric antigen receptors - to target acute lymphoblastic leukaemia. Prof Riddell told the BBC: "Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient's tumour cells. "[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than [...]

Charlotte Parker2016-02-22T12:19:53-07:00February, 2016|Oral Cancer News|

HPV vaccination rates are low, especially in Kansas and Missouri, and cancer experts are alarmed

Source: www.kansascity.comAuthor: Lisa Gutierrez The HPV vaccine is recommended for girls and boys starting at ages 11 to 12. But in state-by-state comparisons, children in Kansas and Missouri rank at or near the bottom of the list. John Amis The Associated Press The University of Kansas Cancer Center recently joined nearly 70 other cancer centers across the country to sound an alarm about the HPV vaccine. Many children still are not getting the recommended vaccine for human papillomavirus, which causes head and neck cancer in men and women, cervical cancer in women and a host of other cancers in both. In Kansas and Missouri, less than 49 percent of girls have received the vaccine, according to the Centers for Disease Control and Prevention. Kansas ranks dead last in the nation, and Missouri is near the bottom. Both states rank low for the number of boys who are vaccinated too. The public call from KU’s cancer center was blunt: The vaccine prevents cancer. What’s the problem? “It absolutely breaks my heart,” said Terry Tsue, physician-in-chief at the University of Kansas Cancer Center. “We have two vaccines against cancers that are caused by virus, the hepatitis A vaccine and the HPV vaccine. Otherwise, we don’t have a vaccine that prevents cancer. “There are thousands and thousands of people dying annually from this disease that could have been prevented had we had this vaccine 30 years ago. We didn’t have it and were so slow in adopting it that for the next [...]

Charlotte Parker2016-02-18T13:37:23-07:00February, 2016|Oral Cancer News|

HPV16 Antibodies Signal Even Better Oral Cancer Outcomes

Source: www.medscape.comAuthor: Neil Osterweil Another prognostic tool may be in the offing for clinicians to use in evaluating patients with oropharyngeal cancers, new research suggests. The presence in serum of three antibodies to human papillomavirus type 16 (HPV16) was predictive of better progression-free and overall survival in these patients, according to Kristina R. Dahlstrom, PhD, from the University of Texas MD Anderson Cancer Center, in Houston, and colleagues. Patients whose serum was positive for the presence of three specific antibodies to "early" (E) proteins involved in replication and growth of HPV16 had dramatically better rates of overall survival (OS) and progression-free survival (PFS) compared with patients whose serum was negative for the antibodies, they reported online June 15 in Clinical Cancer Research. Specifically, for those patients whose serum was positive for any E antibodies, 5-year estimated OS was 87.4%, compared with 42.2% for patients whose sereum was negative for all E antibodies (P < .001). The respective 5-year PFS rates were 82.9% and 46.1% (P < .001). "These results hint at a prognostic stratification of patients with HPV-related oropharynx cancer reflecting humoral immune response to HPV type 16 E proteins and thus may help in choosing immunotherapy approaches for such patients in future," said senior author Erich M. Sturgis, MD, MPH, a surgeon at MD Anderson, in comments to Medscape Medical News. Currently, the serology results are not strong enough to be used as clinical decision tools for choosing current therapies, she added. Their findings also suggest that vaccine-based immunotherapy targeted [...]

Oral Cancer Foundation News Team - A2015-06-17T16:33:41-07:00June, 2015|Oral Cancer News|

NIH-funded study finds new potential drug targets by uncovering a range of molecular alterations in head and neck cancers

Source: www.nih.govAuthor: Staff Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences — with potentially important clinical implications — in head and neck cancers caused by infection with the human papillomavirus (HPV). HPV is the most common sexually transmitted virus in the United States, and the number of HPV-related head and neck cancers has been growing. Almost every sexually active person will acquire HPV at some point in their lives, according to the Centers for Disease Control and Prevention. The researchers also uncovered new smoking-related cancer subtypes and potential new drug targets, and found numerous genomic similarities with other cancer types. Taken together, this study’s findings may provide more detailed explanations of how HPV infection and smoking play roles in head and neck cancer risk and disease development, and offer potential novel diagnostic and treatment directions. The study is the most comprehensive examination to date of genomic alterations in head and neck cancers. The results were published online Jan. 28, 2015 in the journal Nature. TCGA is jointly supported and managed by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both parts of the National Institutes of Health. The U.S. Food and Drug Administration-approved HPV vaccines should be able to prevent the cancers caused by HPV infection in head and neck cancers and elsewhere, including anal cancer, whose incidence has also been increasing. However, these vaccines work by preventing new infections, and the long interval between infection and cancer development make it [...]

Charlotte Parker2015-03-10T10:11:49-07:00March, 2015|Oral Cancer News|

HPV Related Cancers Increase in Men

Source: scientificamerican.comAuthor: Robin Lloyd A vaccine to protect against the most dangerous strains of human papillomavirus (HPV), which cause almost all cervical cancers, as well as many cases of other cancers and genital warts in both sexes, won the approval of the U.S. Food and Drug Administration nearly nine years ago. The Centers for Disease Control and Prevention now recommends that all boys and girls aged 11 or 12 receive the shots. Vaccination campaigns, aimed largely at girls and women, have fallen short of expectations. By 2013 just over half of U.S. females aged 13 to 17 had received at least one dose of either the Gardasil or Cervarix vaccine. For males, that figure was a disappointing 35 percent. Now head and neck cancers associated with the virus are on the rise, leading some experts to recommend that a gender-neutral or male-centric approach might be more effective. HPV is the most prevalent sexually transmitted disease in the U.S. and worldwide, infecting just about all men and women at some point in their lives. Although most people clear the virus naturally, persistent infections with some strains can lead to cancer—usually cervical or oropharyngeal (affecting the back of the throat, tonsils and back of the tongue). HPV-associated cancers make up 3.3 percent of all cancer cases among women and 2 percent of all such cases among men annually in the latest available figures, yet the incidence of virally instigated oropharyngeal and anal cancers is increasing. Ohio State University medical oncologist and epidemiologist Maura [...]

Charlotte Parker2015-02-18T10:56:24-07:00February, 2015|Oral Cancer News|